- Home
- TARA vs DRRX Comparison
TARA vs DRRX Comparison
Compare TARA & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- DRRX
- Stock Information
- Founded
- TARA N/A
- DRRX 1998
- Country
- TARA United States
- DRRX United States
- Employees
- TARA N/A
- DRRX N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- TARA Health Care
- DRRX Health Care
- Exchange
- TARA Nasdaq
- DRRX Nasdaq
- Market Cap
- TARA 52.4M
- DRRX 44.4M
- IPO Year
- TARA N/A
- DRRX 2000
- Fundamental
- Price
- TARA $5.30
- DRRX $0.85
- Analyst Decision
- TARA Strong Buy
- DRRX Buy
- Analyst Count
- TARA 3
- DRRX 2
- Target Price
- TARA $22.67
- DRRX $5.00
- AVG Volume (30 Days)
- TARA 6.6M
- DRRX 124.3K
- Earning Date
- TARA 11-12-2024
- DRRX 11-13-2024
- Dividend Yield
- TARA N/A
- DRRX N/A
- EPS Growth
- TARA N/A
- DRRX N/A
- EPS
- TARA N/A
- DRRX N/A
- Revenue
- TARA N/A
- DRRX $8,594,000.00
- Revenue This Year
- TARA N/A
- DRRX $54.32
- Revenue Next Year
- TARA N/A
- DRRX N/A
- P/E Ratio
- TARA N/A
- DRRX N/A
- Revenue Growth
- TARA N/A
- DRRX N/A
- 52 Week Low
- TARA $1.60
- DRRX $0.48
- 52 Week High
- TARA $10.48
- DRRX $1.88
- Technical
- Relative Strength Index (RSI)
- TARA 63.59
- DRRX 42.97
- Support Level
- TARA $5.27
- DRRX $0.72
- Resistance Level
- TARA $6.39
- DRRX $0.83
- Average True Range (ATR)
- TARA 0.89
- DRRX 0.08
- MACD
- TARA 0.05
- DRRX 0.02
- Stochastic Oscillator
- TARA 36.25
- DRRX 52.40
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .